Vaccinex, Inc.
Polynucleotides encoding anti-CXCL13 antibodies
Last updated:
Abstract:
Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
Status:
Grant
Type:
Utility
Filling date:
13 Apr 2018
Issue date:
10 Nov 2020